PCR Detection of Norovirus in as little as 60* Minutes
Xpert® Norovirus
Norovirus remains one of the most common causes of all viral gastroenteritis in the UK, with over three million cases annually.1,2
Norovirus is uniquely highly transmissible, owing to its low infectious dose (<10 to 100 virions), prolonged viral shedding, medium incubation period (24- to 48-hours) and lack of durable immunity.3 Norovirus-associated gastroenteritis ties up the equivalent of more than twice the daily hospital bed stock in England, with a substantial economic and health impact for the NHS and patients.1
Rapid and accurate diagnosis of norovirus are critical for expediting appropriate infection prevention measures, and help limit onward transmission and service disruption.4
Who Should be Tested?
Diagnostic testing for norovirus should be considered in the following settings:5
Why Test with Fast PCR?
Fast and accurate PCR diagnostics with Cepheid’s GeneXpert® system and Xpert® Norovirus test provide standardised, on-demand, and actionable results in 60 minutes*, enabling healthcare systems with the potential to better manage the risk of norovirus outbreaks, streamline algorithmic-based workflows, enable optimised infection control, and minimise avoidable healthcare costs.6
Antigen-based tests suffer from low sensitivity (<50%), and all negative results require confirmation by molecular PCR methods.6 Fast detection of norovirus with PCR is generally considered the gold standard for performance.6 During outbreak situations, PCR testing of suspected new cases or atypical to inform infection prevention decisions is important.5
Xpert® Norovirus
Detection and differentiation of norovirus genogroup I and genogroup II in as little as 60* minutes.
Impact:
GeneXpert® Systems
Our GeneXpert® family of systems have set a new standard in workflow flexibility, 24/7 accuracy, and user-friendly design.
Our engaging platform delivers:
>30 CE-IVD Tests, One GeneXpert System for Consolidated Infectious Disease PCR Testing
COVID-19, Flu & RSV
Results in 36 minutes
Carbapenem-resistant Bacteria
Results in 50 minutes
C. difficile
Results in 43 minutes
Group B Streptoccoccus
Results in 56 minutes
MRSA
Results in 47 minutes^
TB & Resistance
Results in <90 minutes
Norovirus
Results in 60 minutes*
Vancomycin-resistant Bacteria
Results in 48 minutes
Choose Cepheid as your Trusted Diagnostics NHS Partner Today
Over the last 28 years, Cepheid has partnered with many hospitals, clinics, and laboratories around the world with more than 50,000 systems installed and millions of tests performed, including ~2 million PCR tests delivered to NHS hospitals each year9, changing the lives of patients.
With our solutions, your healthcare organisation can potentially reduce costs, streamline operations, and maximise productivity while prioritising patient health.
Download Norovirus Infographic
Speak to our experts about your norovirus outbreak prevention plan
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
* For positive Norovirus results with early assay termination. Otherwise, full runtime is 90 minutes.
^ For positive MRSA results with early assay termination. Otherwise, full runtime is 70 minutes.
1. Sandmann FG, et al. Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Non-admitted Patients. Clin Infect Dis. 2018 Aug 16;67(5):693-700.
2. Harris JP, et al. Re-assessing the total burden of norovirus circulating in the United Kingdom population. Vaccine. 2017 Feb 7;35(6):853-855.
3. Rovida F, et al. Evaluation of Xpert® Norovirus Assay performance in comparison with real-time RT-PCR in hospitalized adult patients with acute gastroenteritis. Diagn Microbiol Infect Dis. 2016 Aug;85(4):426-427.
4. Gonzalez M, et al. Multicenter evaluation of the Xpert® Norovirus assay for detection of norovirus genogroups I and II in fecal specimens. Journal of Clinical Microbiology. 2015 Dec;54(1):142-147.
5. Gov UK. Guidelines for the management of norovirus outbreaks in acute and community health and social care settings. 2012. https://www.gov.uk/government/publications/norovirus-managing-outbreaks-in-acute-and-community-health-and-social-care-settings
6. Cleary O, et al. Evaluation of the Xpert Norovirus assay for the rapid detection of norovirus genogroups I and II in faecal specimens within a routine laboratory setting. British Journal of Biomedical Science. 2017 Dec:74(3):144-147.
7. Henningsson AJ, et al. Rapid diagnosis of acute norovirus-associated gastroenteritis: evaluation of the Xpert Norovirus assay and its implementation as a 24/7 service in three hospitals in Jönköping County, Sweden. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1867-1871.
8. Dewar S, et al. Point-of-care testing by healthcare workers for detection of meticillin-resistant Staphylococcus aureus, Clostridioides difficile, and norovirus. J Hosp Infect. 2019 Aug;103(4):447-453.
9. 2023 Internal data analysis actual 1.9.
About Cepheid
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.
For more information, visit www.cepheid.com
© 2025 Cepheid. All Rights Reserved.